Accelerate biotechnology

Proteins & antibodies

Proteins & antibodies

Our recombinant protein and antibody capabilities include mammalian cell line generation, production, purification and analysis of recombinant proteins and antibodies manufactured in mammalian systems.

Protein and antibody capabilities

Here at Batavia Biosciences, we generate protein and antibody products as well as perform process development and scale-up of such products in our Woburn facility (MA, USA). Clinical manufacturing of all products is performed in our GMP facility located in the Netherlands. Batavia Biosciences offers unique technologies to increase protein and antibody product yields, decrease process development time, and improve product stability. In general, our strengths include vector construction, stable mammalian cell line generation, small- and large-scale transient production, upstream and downstream process development and scale-up, medium selection, feed strategy optimization, analytical development, product characterization and cGMP manufacturing. Our comprehensive expertise allows us to deliver a complete package comprising of purified product together with all relevant protocols and pivotal biochemical and analytical characterization data.

Proteins and antibodies track record

We have successfully delivered a diverse range of biosimilars including growth factors, fertility hormones, enzymes, anti-cancer fusion proteins, clotting factors, antibodies, antibody fragments, viral proteins and antigenic proteins. For instance, in collaboration with Prof. James Crowe (Pediatrics & Pathology, Microbiology & Immunology Department, Vanderbilt Vaccine Center, Nashville) we have worked on the generation of CHO cell lines expressing potent virus-neutralizing antibodies. Additionally, for COPro Biotech, we have used our STEP® technology to develop a stable biosimilar producer cell line.

Prof. James Crowe, Vanderbilt Vaccine Center: “The proactive thinking and problem-solving mindset at Batavia have been very much appreciated. Getting our potent antibodies from bench to clinic is an absolute priority.”

Yiding Wang, Director Operations, COPro Biotech: “With pleasure we have collaborated with the Batavia team on cell line development. Their STEP® technology is very suitable for generating biosimilar producing cell lines.”

Proteins & antibodies technologies

STEP® technology

Batavia Biosciences STEP technology for increased protein expression

SCOUT® technology

SCOUT technology: High-throughput screening protein viral vector vaccine

Upstream process development

We deliver scalable and robust GMP-compliant production processes for recombinant proteins. Upstream process development for mammalian platforms For small scale, high-throughput productions (microgram to milligram range of proteins), we typically apply our SCOUT® technology. This system integrates high-throughput cell culture using mini bioreactors (spin tubes; 2 - 20 mL working volume) with high throughput purification technology (spin-traps and…

Read more

Downstream process development

We deliver scalable and robust GMP-compliant purification processes for recombinant proteins. Our expertise in downstream processing allows us to develop improved or completely novel purification processes. Hereto, we typically adhere to Design of Experiments (DoE) and Quality by Design (QbD) tools to efficiently anchor purification steps and monitor the key process parameters for scale-up. Downstream…

Read more

Meet the experts

    How important is matrix effect in analyzing bioprocess samples?Meet the Expert: Petra, Analytical Scientist The matrix effect is the effect on an analytical assay caused by all other components of the sample except the specific compound (analyte) to be analyzed. Matrix effects can be observed either as a loss in response – resulting in an underestimation of the amount of…
    The good, the bad, and the ugly in biosimilar developmentMeet the Expert: Wilfried, Scientific Director Whether it concerns a biosimilar, a biobetter, a product to treat a rare genetic disorder or a biothreat counter-measure, product yield from mammalian cell lines is a critical economic driver. Naturally, increased specific productivity – microgram product per cell per day – decreases the cost of…
    Analytical assay development: go ALL the wayMeet the Expert: Gert, Analytical Assay Scientist The truth is; the accuracy and robustness of any process under development or manufacturing outcome is only as good as the reliability of the assays needed to understand the process. The effort involved to get to a comfortable situation where all necessary tests are available,…
Read more

COVID-19 Message

Please read the message from our executive management regarding the precautionary measures at Batavia Biosciences.